跳至主要内容
临床试验/NCT05300724
NCT05300724
进行中(未招募)
不适用

A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Genentech, Inc.144 个研究点 分布在 2 个国家目标入组 400 人2022年5月27日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Age-Related Macular Degeneration
发起方
Genentech, Inc.
入组人数
400
试验地点
144
主要终点
Rate of Conversion from iAMD to nGA /iRORA
状态
进行中(未招募)
最后更新
上个月

概览

简要总结

This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (~144 weeks) for participants.

注册库
clinicaltrials.gov
开始日期
2022年5月27日
结束日期
2027年6月30日
最后更新
上个月
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • For women of childbearing potential, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, during the study for at least 28 days after the last fluorescein injection for the fluorescein angiography (FA) administration
  • Study eye: High-risk intermediate AMD

排除标准

  • Macular disease in either eye with subretinal deposits not typical of AMD
  • Pigmentary abnormalities of the retina in either eye not typical of AMD
  • Atrophy in either eye due to causes other than AMD
  • Study eye: Any concurrent or history of ocular or intraocular condition
  • Study eye: Intraocular surgery, including cataract surgery, within 3 months prior to Day 1
  • Study eye: Retinal tears or peripheral retinal breaks within 3 months prior to Day 1
  • Study eye: Concurrent or history of retinal laser photocoagulation or anti-vascular endothelial growth factor (anti-VEGF) treatment for exudative MNV, diabetic macular edema, retinal vein occlusion, or proliferative diabetic retinopathy
  • Study eye: Presence of choroidal nevus with overlying drusen in the circle with a radius 3600 micrometer centered on the fovea
  • Study eye: Previous participation in interventional clinical trials for GA or early stages of AMD, except for vitamins and minerals, regardless of the route of administration within the last 6 months, except for sham-arm participants
  • Study eye: History of glaucoma surgery, corneal transplant, retinal pigment epithelium tear, retinal tear that involves the macula, retinal detachment

结局指标

主要结局

Rate of Conversion from iAMD to nGA /iRORA

时间窗: Baseline up to 3 years

Rate of Conversion from nGA/iRORA to cRORA/GA

时间窗: Baseline up to 3 years

Rate of Photoreceptor Loss as Assessed by Spectral Domain Optical Coherence Tomography (SD-OCT)

时间窗: Baseline up to 3 years

研究点 (144)

Loading locations...

相似试验